Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Carlos Miguel Cheganças Capela"'
Autor:
Rui Pedrosa, Carlos Miguel Cheganças Capela, Manuel Manita, Ariana Barros, João Sequeira, Ary de Sousa
Publikováno v:
Clinical neuropharmacology. 41(4)
OBJECTIVES The aim of this study was to evaluate postmarketing fingolimod safety and effectiveness in a real-world clinical population. METHODS This was a retrospective, single-center study with active multiple sclerosis patients treated with fingoli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de5f745bbc44d55756ba462200d0bb58
https://pubmed.ncbi.nlm.nih.gov/29927805
https://pubmed.ncbi.nlm.nih.gov/29927805
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 6, p 1639 (2018)
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
International Journal of Molecular Sciences
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
International Journal of Molecular Sciences
"Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system (CNS) probably caused, in most cases, by the interaction of genetic and environmental factors. This review first summarizes some clinical, epidemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d8b0fd6c24a25d79a38b744d3d8daf
http://www.mdpi.com/1422-0067/19/6/1639
http://www.mdpi.com/1422-0067/19/6/1639